Healthcare Industry News: Eisai
News Release - January 23, 2008
Myriad Genetics, Inc. Expands Commercial and Clinical InfrastructureSALT LAKE CITY, UT--(Healthcare Sales & Marketing Network)--Jan 23, 2008 -- Myriad Genetics, Inc. (NasdaqGS:MYGN ) has expanded its commercial and clinical capabilities, the Company said today. Myriad recently named Robert Rubens, M.D., as Vice President of Medical Affairs, and James DeMarco as Vice President of Sales for Myriad Pharmaceuticals, Inc. Myriad has also strengthened its management of clinical development programs by naming Margaret Yu, M.D., as Director of Clinical Research in Oncology and Andrew Beelen, M.D., as Senior Director of Clinical Research in Infectious Diseases.
Robert P. Rubens, M.D., MBA, will oversee professional education, publications, Phase 4 studies, the CNS medical science liaison team, and the medical information functions at Myriad Pharmaceuticals, Inc. He will lead the formulation of strategic approaches to further clinical study programs, including managing investigator-initiated clinical trials and post-marketing studies. Additionally, he will provide medical review of all promotional materials, sales training materials and medical communications. Dr. Rubens joined Myriad from Sepracor, where he served as Executive Medical Director, CNS Medical Affairs and was a member of the Lunesta launch team. Prior to Sepracor, Dr. Rubens was U.S. Medical Director, CNS medical for Pfizer, Inc., and a member of the Relpax launch team. This duty followed a 17 year career in clinical adult neurology practice, during which time he was also a clinical associate professor of neurology at the University of Washington School of Medicine. Dr. Rubens earned his medical degree from the UMDNJ New Jersey Medical School and holds an MBA from the University of Washington where he also completed his medical internship and neurology residency. He did his undergraduate work at The Johns Hopkins University.
James DeMarco is responsible for all sales-related activities for Myriad Pharmaceuticals, Inc. He will formulate the brand strategy to optimize sales of all commercial products and lead the U.S. and worldwide sales organizations, while overseeing functional areas of Field Sales, Sales Training and Sales Operations. Mr. Demarco joins Myriad from Idenix Pharmaceuticals, where he was Vice President, U.S. Sales. His career in pharmaceutical sales has benefitted companies beginning with Schering-Plough and Amgen, then Eisai and Idenix and now Myriad. Mr. DeMarco graduated with a Bachelor's degree from Rutger's University in Economics/Finance and Philosophy.
Margaret K. Yu, M.D., is responsible for the strategic direction of clinical development plans for oncology-related compounds, including Azixa, to ensure successful registration of new drug candidates. Dr. Yu was previously Assistant Professor in the Department of Hematology at the University of Utah. She earned her medical degree at the Medical College of Wisconsin and her undergraduate degree in Biological Sciences from the University of California - Irvine.
Andrew P. Beleen, M.D., is responsible for the overall strategy and direction of clinical development in the infectious disease field, including Vivecon. Dr. Beelen joins Myriad from GlaxoSmithKline, where he was most recently Director, Clinical Pharmacology and Discovery Medicine at their Infectious Diseases Center for Excellence in Drug Discovery. Dr. Beleen earned his medical degree from the State University of New York Health Science Center at Syracuse (aka Upstate Medical University) and his undergraduate degree from the Albany College of Pharmacy.
"I am pleased to extend a warm welcome to all our new employees," said Adrian Hobden, Ph.D., President of Myriad Pharmaceuticals, Inc. "Their addition to our team greatly enhances our ability to optimize the clinical development and commercial launch of our pipeline of therapeutic products."
Myriad Genetics, Inc. is a biopharmaceutical company focused on the development of novel healthcare products. The Company develops and markets predictive medicine products, and is developing and intends to market therapeutic products. Myriad's news and other information are available on the Company's Web site at www.myriad.com.
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include statements relating to the Company's capabilities in commercializing a variety of therapeutics; the Company's ability to further clinical study programs; the ability of the Company to formulate brand strategies which will optimize sales of commercial products; the Company's ability to ensure successful registration of new drug candidates; the Company's confidence in the Flurizan program and estimation of likelihood of success in the Alzheimer's disease phase 3 trial; and the ability of the Company to commercially introduce Flurizan. These risks and uncertainties include, but are not limited to, our inability to further identify, develop and achieve commercial success for new products and technologies; our ability to discover drugs that are safer and more efficacious than our competitors; our ability to develop molecular diagnostic products that help assess which patients are subject to greater risk of developing diseases and who would therefore benefit from new preventive therapies; the possibility of delays in the research and development necessary to select drug development candidates and delays in clinical trials; the risk that clinical trials may not result in marketable products; the risk that we may be unable to successfully finance and secure regulatory approval of and market our drug candidates, or that clinical trials will be completed on the timelines we have estimated; uncertainties about our ability to obtain new corporate collaborations and acquire new technologies on satisfactory terms, if at all; the development of competing products and services; our ability to protect our proprietary technologies; patent-infringement claims; risks of new, changing and competitive technologies and regulations in the United States and internationally; and other factors discussed under the heading "Risk Factors" contained in Item 1A in our Annual Report on Form 10-K for the year ended June 30, 2007, which has been filed with the Securities and Exchange Commission, as well as any updates to those risk factors filed from time to time in our Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. All information in this press release is as of the date of the release, and Myriad undertakes no duty to update this information unless required by law.
Source: Myriad Genetics
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.